When is NAGE's latest earnings report released?
The most recent financial report for Niagen bioscience inc (NAGE) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NAGE's short-term business performance and financial health. For the latest updates on NAGE's earnings releases, visit this page regularly.
Where does NAGE fall in the P/E River chart?
According to historical valuation range analysis, Niagen bioscience inc (NAGE)'s current price-to-earnings (P/E) ratio is 27.15, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of NAGE?
According to the latest financial report, Niagen bioscience inc (NAGE) reported an Operating Profit of 4.24M with an Operating Margin of 12.46% this period, representing a growth of 164.42% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is NAGE's revenue growth?
In the latest financial report, Niagen bioscience inc (NAGE) announced revenue of 33.99M, with a Year-Over-Year growth rate of 32.86%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does NAGE have?
As of the end of the reporting period, Niagen bioscience inc (NAGE) had total debt of 3.06M, with a debt ratio of 0.03. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does NAGE have?
At the end of the period, Niagen bioscience inc (NAGE) held Total Cash and Cash Equivalents of 64.29M, accounting for 0.66 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does NAGE go with three margins increasing?
In the latest report, Niagen bioscience inc (NAGE) achieved the “three margins increasing” benchmark, with a gross margin of 64.5%%, operating margin of 12.46%%, and net margin of 13.5%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess NAGE's profit trajectory and future growth potential.
Is NAGE's EPS continuing to grow?
According to the past four quarterly reports, Niagen bioscience inc (NAGE)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.06. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of NAGE?
Niagen bioscience inc (NAGE)'s Free Cash Flow (FCF) for the period is 3.67M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 5.58% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
